Pureos Bioventures closes US$170m fund
Newly formed venture capitalist Pureos Bioventures has set up a US$170m fund dedicated to Swiss and European drug developers.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1345 entries already.
Entries by Thomas Gabrielczyk
Biotechs request money for COVID therapeutics
/in News/by Thomas GabrielczykGerman biotech companies and their industry association BIO Deutschland have called for appropriate investments into clinical COVID-19 therapies.
Polyneuron Pharmaceuticals AG extends Series A financing
/in News/by Thomas GabrielczykSwiss auto-immunity specialist Polyneuron Pharmaceuticals AG has received CHF14m from HBM Healthcare Investments.
Mabion to licence COVID-19 jab from Vaxine Pty Ltd
/in News/by Thomas GabrielczykPolish Mabion SA and Australian Vaxine Pty Ltd to develop Covax-19
MiNA Therapeutic bags £23m financing
/in News/by Thomas GabrielczykRNA therapeutics specialist MiNA Therapeutics plc has secured £23m in a Series A financing to push development its first-in-class small activating RNA (saRNA) candidates.
Vaccine developers unite to stand with science
/in News/by Thomas GabrielczykNine CEOs of COVID-19 vaccines have assured that safety of vaccinated individuals remains their top priority in development of the first COVID-19 vaccines.
Scope Fluidics gets EIB loan for infection diagnostics
/in News/by Thomas GabrielczykThe European Investment Bank has lend up to 10m to Polish microbial diagnostics specialist Scope Fluidics AS.
COVID-19: Roche AG launches antigen rapid test
/in News/by Thomas GabrielczykRoche has announced to launch a SARS-CoV-2 point-of-care antigen test this month co-developed with SD Biosensor Inc. (South Korea).
Unilever to replace fossil carbon in cleaning products
/in News/by Thomas GabrielczykUnilever has announced to invest 1bn globally to eliminate fossil fuels as a source of carbon in its cleaning products by 2030.
Bioversys bags 17.7m financing
/in News/by Thomas GabrielczykSwiss BioVersys AG has secured a CHF19m Series B financing to push clinincal development of two antiinfectives against drug-resistant pathogens.